Viral cystitis is inflammation of the bladder caused by a virus rather than the bacteria that drive most urinary tract infections. The condition is overwhelmingly a problem for people whose immune systems are suppressed, particularly those who have undergone stem cell or organ transplantation. BK virus, adenovirus, and cytomegalovirus are the most common culprits, and in transplant settings the resulting hemorrhagic cystitis can range from mild, self-limiting blood in the urine to a life-threatening bleed that resists standard treatments.1PubMed Central. Viral lower urinary tract infections Understanding which virus is responsible matters because the approach to treatment differs sharply depending on the pathogen, the patient’s immune status, and how severe the bleeding becomes.
Which Viruses Are Involved
The roster of viruses that can infect the bladder lining is surprisingly short. The most frequently identified agents are BK virus (a human polyomavirus that lies dormant in the kidneys of most adults), adenovirus (particularly types 11 and 21), cytomegalovirus (CMV), and herpes simplex virus types 1 and 2.2Urogenital Tract Infection. Virus in the Urine of Healthy People and Patients with Infectious Diseases Of these, BK virus dominates in the transplant population. It already lives in the urinary tract of a large share of healthy people, doing nothing harmful as long as the immune system keeps it in check. When immunosuppressive drugs knock that surveillance down, BK virus can reactivate aggressively and attack the bladder wall.
Adenovirus gets attention mainly in children with otherwise healthy immune systems. Studies in Japan and the United States found that adenovirus type 11 was present in the urine of roughly a quarter to half of children with acute hemorrhagic cystitis, depending on the cohort studied.3PubMed Central. A review of adenoviruses in the etiology of acute hemorrhagic cystitis In transplant recipients, adenovirus types 11 and 37 have both been isolated from the urine of patients who develop bloody bladder inflammation.4PubMed. Acute hemorrhagic cystitis by adenovirus type 11 with and without type 37 after kidney transplantation
CMV cystitis is rarer but documented in patients with advanced HIV infection and in people receiving immunosuppressive drugs for kidney disease. In one reported case, a young HIV-positive woman with gross blood in her urine underwent cystoscopy that revealed ulcerative lesions; biopsy confirmed CMV by immunohistochemistry.5African Journal of Urology. Haemorrhagic cystitis due to cytomegalovirus in a patient with AIDS Another patient, who was receiving cyclophosphamide for kidney disease rather than for transplant, developed CMV cystitis confirmed by bladder biopsy and blood PCR testing. Intravenous ganciclovir cleared the virus and stopped the bleeding within days.6Saudi Journal of Kidney Diseases and Transplantation. Cytomegalovirus-related Cystitis in a Patient with Membranous Glomerulonephritis Receiving Cyclophosphamide
Why Transplant Patients Bear the Brunt
Viral cystitis occasionally appears in otherwise healthy people, but the overwhelming burden falls on those who are immunosuppressed. After a stem cell transplant, the immune system is essentially rebuilt from scratch, and the months of profound suppression that follow create a window in which dormant viruses reactivate. BK virus is the textbook example: its reactivation during the period of maximal post-transplant immune suppression is a central driver of late-onset hemorrhagic cystitis.7PubMed. Prevention and management of BK-virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation
Not all transplant recipients carry the same risk. A study of patients who tested positive for BK virus before their transplant found that those who received haploidentical or cord-blood grafts with intensive chemotherapy conditioning had a dramatically higher rate of hemorrhagic cystitis (about 58%) compared with all other recipients (about 7%).8PubMed Central. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type The combination of a vigorous conditioning regimen that damages the bladder lining and a donor type that prolongs immune recovery creates the perfect storm for virus-driven bladder inflammation.
Kidney transplant recipients face a related but somewhat different picture. For them, the concern is not just bladder damage but also viral spread into the transplanted kidney itself. Adenovirus type 11, for instance, was isolated from the urine of renal allograft recipients, though only a fraction developed overt hemorrhagic cystitis.9PubMed. Acute hemorrhagic cystitis caused by adenovirus type 11 after renal transplantation Whether a patient goes from silent viral shedding to full-blown bladder inflammation depends on the intensity of immune suppression, the conditioning regimen used, and probably some individual variation in how the bladder’s mucosal defenses hold up.
Herpes Viruses and the Bladder’s Nerve Supply
Herpes simplex and varicella-zoster viruses affect the bladder differently from BK virus and adenovirus. Rather than directly attacking the bladder wall, they often target the sacral nerve roots that control bladder function. The result can be acute urinary retention, where the bladder fills but the patient cannot urinate, rather than bloody urine. In a series of seven patients with herpes-related urinary retention, all showed an absent bladder sensation on testing, and voiding function took four to six weeks to recover.10PubMed. Urinary retention due to herpes virus infections
HSV-1 is less commonly recognized as a urinary tract pathogen, but at least one documented case involved a young, immunocompetent man with fever, low-back pain, and complete urinary retention. PCR testing of both blood and spinal fluid came back positive for HSV-1, and cystoscopy showed reddened patches on the bladder walls.11PubMed. Acute urinary retention due to HSV-1: a case report This pattern is worth knowing about because the presentation looks nothing like a typical bladder infection, and without specific viral testing the diagnosis is easy to miss.
SARS-CoV-2 and the Bladder
The COVID-19 pandemic raised a less publicized question: can SARS-CoV-2 infect the bladder? The virus enters cells through ACE2 receptors, and the bladder’s lining expresses these receptors at a density of about 2.4%, which is above the threshold thought to make a tissue susceptible.12Continence Reports. Lower Urinary Tract Symptoms (LUTS) and COVID-19 Clinicians reported cases of urinary frequency during COVID-19 illness that, after excluding every other cause, appeared attributable to a viral cystitis from SARS-CoV-2 itself.13PubMed Central. Urinary Frequency as a Possibly Overlooked Symptom in COVID-19 Patients: Does SARS-CoV-2 Cause Viral Cystitis? The evidence remains thin, based on case observations rather than large studies, but the biology is plausible. Other respiratory viruses, including influenza B, have also been linked to bladder symptoms in isolated cases. One otherwise healthy adult man developed painful urination, frequency, and blood in his urine nine days after recovering from influenza B, with no evidence of a bacterial cause.14PubMed Central. Uncomplicated Cystitis in an Adult Male Following Influenza B Virus Infection
How It Is Diagnosed
Standard urine cultures will come back negative in viral cystitis because they are designed to grow bacteria. The key diagnostic tool is a molecular test, usually a real-time PCR assay run on a urine or blood sample. PCR allows clinicians not only to identify which virus is present but also to measure how much virus is circulating, which helps guide treatment decisions. In transplant centers, periodic screening for BK viruria is common practice even before symptoms appear, since catching a rising viral load early can prompt a preemptive change in immunosuppressive drugs before full-blown hemorrhagic cystitis develops.
Cystoscopy, where a thin camera is passed into the bladder, can show the physical damage: patchy redness, mucosal ulceration, or clots filling the bladder in severe cases. In CMV cystitis, biopsies reveal the characteristic enlarged cells with intranuclear inclusions that give the virus its name (“cytomegalovirus” literally means “large-cell virus”).15African Journal of Urology. Haemorrhagic cystitis due to cytomegalovirus in a patient with AIDS Tissue biopsy is not always needed, but when the virus involved is unclear or the clinical picture is unusual, it can confirm what PCR alone cannot.
Children After Stem Cell Transplant
Pediatric transplant recipients are a particularly well-studied group. In one cohort, viral DNA appeared in the urine of about 55% of children after a stem cell transplant, and roughly a quarter went on to develop hemorrhagic cystitis. BK virus was present in about 80% of those cases, adenovirus in about 14%, and JC virus in a small minority. Every child who shed adenovirus in the urine developed hemorrhagic cystitis, making adenoviruria especially ominous in this population.16PubMed. Incidence, clinical outcome, and management of virus-induced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation
Symptoms typically appear a few weeks after transplant and can last anywhere from about 10 to 38 days, depending on severity. Most children develop moderate hemorrhagic cystitis, but a subset develops severe bleeding with clots that can obstruct urine flow, sometimes requiring intensive intervention.17Clinical and Experimental Pediatrics. BK virus-associated hemorrhagic cystitis after pediatric stem cell transplantation In a single-center study of 12 children who developed BK-virus hemorrhagic cystitis at a median of 37 days post-transplant, intravenous cidofovir produced clinical improvement in all cases, with only one episode of drug-related toxicity that resolved on its own.18PubMed. Treatment of BK virus-associated hemorrhagic cystitis in pediatric hematopoietic stem cell transplant recipients with cidofovir
Treatment With Cidofovir
No antiviral drug is specifically approved for BK-virus hemorrhagic cystitis, but cidofovir has become the most widely used off-label option. It can be given intravenously or instilled directly into the bladder. Across published studies involving more than 200 patients, complete response rates have ranged from about 60% to 100%, regardless of whether the drug was given through a vein or into the bladder.19PubMed. Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation
The chief drawback is kidney toxicity. In one retrospective study, about a third of patients experienced some degree of kidney injury during treatment, and several had to stop or switch to intravesical dosing because of worsening kidney function.20PubMed. Efficacy of Cidofovir in Treatment of BK Virus-Induced Hemorrhagic Cystitis in Allogeneic Hematopoietic Cell Transplant Recipients Instilling cidofovir directly into the bladder was initially hoped to sidestep kidney damage altogether, but kidney injury can still occur with intravesical dosing, possibly because some drug is absorbed through the inflamed bladder wall. A larger intravesical study found that about 88% of patients improved, with the main side effect being bladder spasms in roughly 12% of cases.21PubMed. Intravesicular Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis Following Hematopoietic Stem Cell Transplantation Patients with extremely high viral loads and severe hemorrhagic cystitis were less likely to achieve complete clearance, underscoring that earlier intervention tends to produce better outcomes.
Reducing Immunosuppression
Because viral cystitis is fundamentally a disease of immune failure, one of the most logical interventions is to ease back on the drugs that are suppressing the patient’s immune system. This is easier said than done in transplant recipients, where reducing immunosuppression risks organ rejection. Still, retrospective data show that meaningful reductions in common immunosuppressive drugs can drive BK viral loads down sharply. In one series of kidney transplant recipients, cutting the doses of two widely used drugs by about 40-44% produced a significant decline in BK virus DNA levels over roughly six months, with only a small minority (about 13%) experiencing rejection episodes, all of which were treated successfully.22PubMed Central. BK viral infection: A review of management and treatment
In non-renal transplant settings, the same principle holds. A small series of non-kidney transplant patients with BK-virus cystitis saw viral loads drop after their immunosuppressive regimens were trimmed back.23PubMed Central. Symptomatic BK virus cystitis in non-renal transplant recipients The balancing act between controlling the virus and avoiding rejection requires close monitoring, but the evidence consistently points toward immune reconstitution as the single most important factor in clearing the infection.
Virus-Specific T-Cell Therapy
One of the more exciting developments in this space is adoptive T-cell therapy, where immune cells trained to recognize BK virus are manufactured from a donor and infused into the patient. A study of 59 evaluable patients who received third-party BK-virus-specific T cells for hemorrhagic cystitis after a stem cell transplant found an overall response rate of about 68% at two weeks, climbing to roughly 82% by day 45. No patient who initially responded lost that response. The safety profile was reassuring: there were no cases of severe graft-versus-host disease, graft failure, or infusion reactions. When compared with standard care in a matched analysis, patients who received the T cells had higher response rates at every follow-up point and needed fewer blood transfusions.24PubMed Central. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation
Smaller studies have confirmed the feasibility of producing these BK-virus-targeted T cells from healthy donors using synthetic peptide mixtures, showing that the cells can proliferate, produce the right immune signals, and kill virus-infected target cells in laboratory tests.25PubMed Central. In Vitro Generation of BK polyomavirus-specific T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantation Early clinical experience in the particularly difficult setting of haploidentical transplant recipients, where BK-virus cystitis is especially common, has likewise suggested that the approach is both safe and effective.26PubMed. BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation The logistics are still complex and the therapy is not yet widely available, but it represents a genuinely different strategy: rather than trying to kill the virus directly, you rebuild the specific arm of the immune system that should have been handling it all along.
Supportive Measures and Last-Resort Procedures
For patients with moderate hemorrhagic cystitis, supportive care is often the first line: vigorous hydration, continuous bladder irrigation to flush clots, and pain management. These measures buy time for antiviral treatment or immune reconstitution to take effect. Hyperbaric oxygen therapy has been explored for refractory cases. In a retrospective analysis of 25 patients who underwent hyperbaric oxygen sessions for hemorrhagic cystitis that did not respond to other treatments, complete healing was seen in 11 and improvement in 7. Patients who completed seven or more sessions benefited most.27Diving and Hyperbaric Medicine. Hyperbaric oxygen treatment for refractory haemorrhagic cystitis occurring after chemotherapy and haematopoietic stem cell transplantation
When bleeding becomes life-threatening and nothing else works, interventional radiologists can perform selective embolization of the arteries feeding the bladder, cutting off the blood supply to the inflamed tissue. This approach has been described as a safe and effective option that can spare severely ill patients from emergency surgery such as bladder removal.28PubMed. Superselective vesical artery embolization in the management of intractable hematuria secondary to hemorrhagic cystitis It is a bailout procedure, used when the alternative would be cystectomy in a patient who is often already critically ill from the underlying transplant process.29Journal of Clinical Interventional Radiology ISVIR. Selective Vesical Artery Embolization in Refractory BK Virus Hemorrhagic Cystitis
Complications Beyond the Bladder
Severe or prolonged viral cystitis does not always stay confined to the bladder. One documented complication is bilateral ureteral narrowing caused by BK-virus-driven overgrowth of bladder tissue at the points where the ureters enter the bladder. In one case, a patient in remission from leukemia developed late-onset hydronephrosis, where urine backed up into both kidneys because the ureteral openings had been gradually blocked by virus-induced tissue proliferation.30PubMed Central. Hydronephrosis Resulting from Bilateral Ureteral Stenosis: A Late Complication of Polyoma BK Virus Cystitis? This kind of structural damage is a reminder that the consequences of viral cystitis can outlast the acute episode itself, especially in children and young adults who have decades of bladder function ahead of them.
Vaccine Research
Because no approved antiviral reliably clears BK virus, and because treatment options carry real toxicity, prevention through vaccination is an active area of research. One promising approach uses virus-like particles, the same technology behind HPV vaccines. In macaques, a multivalent vaccine covering multiple BK-virus genotypes plus JC virus produced neutralizing antibody levels above a proposed protective threshold in every animal tested. A booster dose pushed titers even higher, and those levels held steady for nearly two years with no adverse events observed.31PubMed Central. A multivalent polyomavirus vaccine elicits durable neutralizing antibody responses in macaques The investigators proposed that a clinical trial in patients awaiting kidney transplant would be a logical next step.
A separate line of work is exploring mRNA-based vaccines designed to boost the T-cell arm of immunity against BK virus, specifically targeting a viral protein called the large T antigen. Early laboratory work has shown that mRNA constructs encoding fragments of this protein can expand T cells that recognize and kill BK-virus-infected human kidney cells.32PubMed. Designing CD8 T cell messenger RNA vaccines targeting the viral large T antigen to prevent BK polyomavirus disease after kidney transplantation Neither vaccine approach has reached human trials yet, but the combination of an antibody-stimulating vaccine and a T-cell-stimulating vaccine could eventually offer layered protection for the transplant patients who need it most.